Przeciwciała przeciwko dekarboksylazie glutaminianowej w surowicy

Przewidywanie ciężkości COVID-19 za pomocą swoistego przeciwciała nukleokapsydowego i wskaźnika czynnika ryzyka choroby

Steidzami nepieciešamas efektīvas metodes COVID-19 slimības trajektoriju prognozēšanai. Šeit ar enzīmu saistītu imūnsorbentu testu (ELISA) un koronavīrusa antigēna mikroelementu (COVAM) analīze uzrādīja antivielu epitopus COVID-19 pacientu (n = 86) plazmā, kuriem bija plašs slimību stāvoklis. Eksperimentos tika identificētas antivielas pret 21 atlikuma epitopu no nukleokapsīda (saukts par Ep9), kas saistīts ar smagu slimību, ieskaitot uzņemšanu intensīvās terapijas nodaļā (ICU), nepieciešamību pēc ventilatoriem vai nāvi.

Svarīgi, ka anti-Ep9 antivielas var noteikt 6 dienu laikā pēc simptomu parādīšanās un dažreiz 1 dienas laikā. Turklāt anti-Ep9 antivielas korelē ar dažādām blakusslimībām un imūnās hiperaktivitātes pazīmēm. Mēs ieviešam vienkārši aprēķināmu slimības riska faktora rādītāju, lai aprēķinātu katra pacienta blakusslimības un vecumu. Pacientiem ar anti-Ep9 antivielām rādītāji virs 3,Zero paredz smagākus slimības iznākumus ar 13,42 varbūtības koeficientu (96,7% specifiskumu).

Rezultāti ir pamats jauna veida COVID-19 prognostikai, lai ļautu agri identificēt un šķirot augsta riska pacientus. Šāda informācija varētu palīdzēt efektīvākai terapeitiskai iejaukšanai. SVARĪBA COVID-19 pandēmija ir izraisījusi vairāk nekā divus miljonus nāves gadījumu visā pasaulē. Neskatoties uz centieniem cīnīties ar vīrusu, šī slimība joprojām pārņem slimnīcas ar smagi slimiem pacientiem.

COVID-19 diagnostiku var viegli veikt, izmantojot daudzas uzticamas testēšanas platformas; tomēr prognostiskā prognozēšana joprojām ir nenotverama. Šajā nolūkā mēs identificējām īsu epitopu no SARS-CoV-2 nukleokapsīda proteīna, kā arī slimības riska faktora rādītāju, pamatojoties uz blakusslimībām un vecumu. Antivielu klātbūtne, kas specifiski saistās ar šo epitopu, kā arī vērtējuma robežvērtība var paredzēt smagus COVID-19 rezultātus ar 96,7% specifiskumu.

Związek między poziomami alarmin w surowicy a wskaźnikami specyficznymi dla choroby u pacjentów z zapaleniem naczyń związanym z cytoplazmatycznymi przeciwciałami przeciw neutrofilom

Priekšvēsture / mērķis: Mēs novērtējām sakarību starp seruma alarmīna līmeni un slimības specifiskajiem rādītājiem pacientiem ar anti-neitrofilo citoplazmas antivielu (ANCA) saistīto vaskulītu (AAV).

Pacienti un metodes: Tika izmantoti serumi un dati par 79 pacientiem. AAV specifiskajiem indeksiem tika savākts Birmingemas vaskulīta aktivitātes rādītājs (BVAS), piecu faktoru rādītājs (FFS) un vaskulīta bojājuma indekss (VDI), kā arī četru alarmīnu līmenis (hepatomas atvasināts augšanas faktors, augstas mobilitātes grupas 1. proteīns) , S100A9 un S100A12) tika mērīti, izmantojot ar enzīmu saistītu imūnsorbentu testu. Tika novērtētas asociācijas starp alarminu līmeni, AAV specifiskajiem indeksiem un iekaisuma laboratorijas marķieriem.

Rezultāti: S100A9 līmenis būtiski korelēja ar C-reaktīvo olbaltumvielu līmeni (r = 0,316, p = 0,005) un S100A12 līmenis korelēja ar VDI (r = 0,232, p = 0,040), kas bija konsekventa pacientu apakšgrupā ar mieloperoksidāzi (perinukleārā) ) -ANCA pozitivitāte. Citas asociācijas starp alarminu līmeni un BVAS, FFS un VDI netika atrastas.

Secinājums: seruma S100A12 līmenis bija saistīts ar orgānu bojājumiem AAV, īpaši mieloperoksidāzes (perinukleārās) -ANCA pozitīviem pacientiem.

bernsklepo
bernsklepo

Recombinant Human IGF BP7

HEGFP-0907 5ug Ask for price

IGF BP3 antibody

70R-IR022 50 ug
EUR 327.6
Description: Affinity purified Rabbit polyclonal IGF BP3 antibody

IGF BP5 antibody

70R-IR023 50 ug
EUR 327.6
Description: Affinity purified Rabbit polyclonal IGF BP5 antibody

IGF BP7 antibody

70R-IR024 50 ug
EUR 327.6
Description: Affinity purified Rabbit polyclonal IGF BP7 antibody

IGF-BP3, Human

HY-P7020 10ug
EUR 280.8

IGF-BP5, Human

HY-P7021 50ug
EUR 721.2

IGF-BP3, human

RC216-12B3 5ug
EUR 125.26

Rabbit Anti Human RIPK1 Monoclonal Clone IGF-18

IRBAHURIPK1IGF18C100UL each
EUR 496
Description: Rabbit Anti Human RIPK1 Monoclonal Clone IGF-18

IGF BP2 protein

30R-AI105 20 ug
EUR 327.6
Description: Purified recombinant Human IGF BP2 protein

IGF BP6 protein

30R-AI106 25 ug
EUR 327.6
Description: Purified recombinant Human IGF BP6 protein

IGF BP7 protein

30R-AI120 25 ug
EUR 327.6
Description: Purified recombinant Human IGF BP7 protein

IGF BP1 protein

30R-AI121 25 ug
EUR 327.6
Description: Purified recombinant Human IGF BP1 protein

IGF BP3 protein

30R-AI122 25 ug
EUR 327.6
Description: Purified recombinant Human IGF BP3 protein

IGF BP5 protein

30R-AI124 25 ug
EUR 327.6
Description: Purified recombinant Human IGF BP5 protein

IGF-1, Human

HY-P7018 10ug
EUR 129.6

IGF-2, Human

HY-P7019 100ug
EUR 432

IGF-1, human

RC216-12 1mg
EUR 451.5

Antibody for Human IGF-1

SPC-699D-ALP 0.1mg
EUR 472.8
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to Alkaline Phosphatase.

Antibody for Human IGF-1

SPC-699D-DY350 0.1mg
EUR 496.8
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to Dylight 350.

Antibody for Human IGF-1

SPC-699D-DY405 0.1mg
EUR 483.6
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to Dylight 405.

Antibody for Human IGF-1

SPC-699D-DY488 0.1mg
EUR 471.6
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to Dylight 488.

Antibody for Human IGF-1

SPC-699D 0.1mg
EUR 424.8
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is unconjugated.

Antibody for Human IGF-1

SPC-699D-A390 0.1mg
EUR 481.2
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to ATTO 390.

Antibody for Human IGF-1

SPC-699D-A488 0.1mg
EUR 480
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to ATTO 488.

Antibody for Human IGF-1

SPC-699D-A565 0.1mg
EUR 480
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to ATTO 565.

Antibody for Human IGF-1

SPC-699D-A594 0.1mg
EUR 480
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to ATTO 594.

Antibody for Human IGF-1

SPC-699D-A633 0.1mg
EUR 480
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to ATTO 633.

Antibody for Human IGF-1

SPC-699D-A655 0.1mg
EUR 480
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to ATTO 655.

Antibody for Human IGF-1

SPC-699D-A680 0.1mg
EUR 480
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to ATTO 680.

Antibody for Human IGF-1

SPC-699D-A700 0.1mg
EUR 480
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to ATTO 700.

Antibody for Human IGF-1

SPC-699D-APC 0.1mg
EUR 478.8
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to APC .

Antibody for Human IGF-1

SPC-699D-APCCY7 0.1mg
EUR 565.2
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to APC/Cy7.

Antibody for Human IGF-1

SPC-699D-BI 0.1mg
EUR 475.2
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to Biotin.

Antibody for Human IGF-1

SPC-699D-DY594 0.1mg
EUR 474
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to Dylight 594.

Antibody for Human IGF-1

SPC-699D-DY633 0.1mg
EUR 468
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to Dylight 633.

Antibody for Human IGF-1

SPC-699D-FITC 0.1mg
EUR 470.4
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to FITC.

Antibody for Human IGF-1

SPC-699D-HRP 0.1mg
EUR 465.6
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to HRP.

Antibody for Human IGF-1

SPC-699D-P594 0.1mg
EUR 488.4
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to PE/ATTO 594.

Antibody for Human IGF-1

SPC-699D-PCP 0.1mg
EUR 478.8
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to PerCP.

Antibody for Human IGF-1

SPC-699D-RPE 0.1mg
EUR 476.4
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to RPE .

Antibody for Human IGF-1

SPC-699D-STR 0.1mg
EUR 477.6
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to Streptavidin.

Antibody for Human IGF-1

SPC-699S 0.012mg
EUR 78
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is unconjugated.

Human Salivary IGF(salivary IGF) ELISA Kit

QY-E05383 96T
EUR 433.2

IGF-I, Human

E34M113H 20 μg
EUR 155
Description: Recombinant Human Cytotoxic T-lymphocyte Protein 4 is produced by our Mammalian expression system and the target gene encoding Lys36-Asp161 is expressed with a Flag tag at the C-terminus.

IGF-II, Human

E34M114H 5 μg
EUR 155

Human IGF-1 LR3

SP-89927-100 100 ug
EUR 270

PE anti-human CD221 (IGF-1R)

E16FHP221-025 25 tests
EUR 476.67
Description: Available in various conjugation types.

PE anti-human CD221 (IGF-1R)

E16FHP221-100 100 tests
EUR 1083.33
Description: Available in various conjugation types.

Recombinant Human IGF-1

HEGFP-0901 100ug Ask for price

Recombinant Human IGF-2

HEGFP-0908 10ug Ask for price

IGF-BP2, human recombinant

7165-10 each
EUR 301.2

IGF-BP2, human recombinant

7165-50 each
EUR 1123.2

IGF-BP7, human recombinant

7167-10 each
EUR 248.4

IGF-BP7, human recombinant

7167-50 each
EUR 810

IGF-BP6, human recombinant

7350-20 each
EUR 444

IGF-BP1, human recombinant

4717-100 each
EUR 744

IGF-BP1, human recombinant

4717-1000 each
EUR 3778.8

IGF-BP1, human recombinant

4717-25 each
EUR 307.2

IGF-BP3, human recombinant

4720-100 each
EUR 744

IGF-BP3, human recombinant

4720-1000 each
EUR 3778.8

IGF-BP3, human recombinant

4720-25 each
EUR 307.2

IGF-BP5, human recombinant

4723-100 each
EUR 744

IGF-BP5, human recombinant

4723-1000 each
EUR 3778.8

IGF-BP5, human recombinant

4723-25 each
EUR 307.2

Purified anti-human CD221 (IGF-1R)

E16FHU221-100U 100 μg
EUR 520
Description: Available in various conjugation types.

IGF-1, human recombinant

P1016-.02 20 µg
EUR 309.6
Description: Insulin-like growth factor I (IGF-1) is a polypeptide endocrine hormone structurally similar to insulin and is mainly produced in the liver when stimulated by growth hormone. IGF-1 is a growth factor that stimulates the proliferation of various cell types including muscle, bone, and cartilage tissue

IGF-1, human recombinant

P1016-.1 100 µg
EUR 915.6
Description: Insulin-like growth factor I (IGF-1) is a polypeptide endocrine hormone structurally similar to insulin and is mainly produced in the liver when stimulated by growth hormone. IGF-1 is a growth factor that stimulates the proliferation of various cell types including muscle, bone, and cartilage tissue

Human IGF-I monoclonal antibody

MAM1 500 µg
EUR 358.8

Anti-Rat IGF-1 Antibody

5121-100 each
EUR 379.2

Anti-Rat IGF-1 Antibody

5121-30T each
EUR 175.2

rec IGF-I (human)

H-5555.0050 50.0µg
EUR 290.4
Description: CAS# [67763-96-6]

rec IGF-I (human)

H-5555.0100 100.0µg
EUR 457.2
Description: CAS# [67763-96-6]

rec IGF-I (human)

H-5555.0500 0.5mg
EUR 1720.8
Description: CAS# [67763-96-6]

Human IGF-BP1 ELISA kit

E22-HC145.48 48T
EUR 295

Human IGF-BP1 ELISA kit

E22-HC145.96 96T
EUR 395

Human IGF-I Protein

abx060791-100ug 100 ug
EUR 560.4

Biotinyl Human IGF-I

AQU010 10 µg
EUR 303.6

Biotinyl Human IGF-I

AQU050 50 µg
EUR 415.2

Biotinyl Human IGF-I

AQU100 100 µg
EUR 637.2

Biotinyl Human IGF-I

AQU500 500 µg
EUR 1305.6

Human [Ala31] IGF-I

AIU020 20 µg
EUR 303.6

Human [Ala31] IGF-I

AIU100 100 µg
EUR 415.2

Human [Leu60] IGF-I

ABU020 20 µg
EUR 303.6

Human [Leu60] IGF-I

ABU100 100 µg
EUR 415.2

Human [Arg6] IGF-II

GU020 20 µg
EUR 303.6

Human [Leu24] IGF-I

ZU020 20 µg
EUR 303.6

Human [Leu24] IGF-I

ZU100 100 µg
EUR 415.2

Recombinant Human IGF-2/ IGF-II Protein, GST, E.coli-1mg

QP8601-ec-1mg 1mg
EUR 1958.4

Recombinant Human IGF-2/ IGF-II Protein, GST, E.coli-10ug

QP8601-ec-10ug 10ug
EUR 240

Recombinant Human IGF-2/ IGF-II Protein, GST, E.coli-50ug

QP8601-ec-50ug 50ug
EUR 315.6

Human [Leu27]IGF-II

TU100 100 µg
EUR 415.2

Recombinant Human IGF-2/ IGF-II Protein, GST, E.coli-100ug

QP8601-ec-100ug 100ug
EUR 489.6

Recombinant Human IGF-2/ IGF-II Protein, GST, E.coli-200ug

QP8601-ec-200ug 200ug
EUR 760.8

Recombinant Human IGF-2/ IGF-II Protein, GST, E.coli-500ug

QP8601-ec-500ug 500ug
EUR 1272

Human IGF-2 ELISA Kit

EHI0307 96Tests
EUR 625.2

Human IGF-1 ELISA Kit

RK00160 96 Tests
EUR 625.2

Human IGF-1 ELISA Kit

E28L0569 96T
EUR 666.67

Human IGF-1 ELISA KIT

E42EH-82 96T/48T Ask for price

Recombinant Human IGF-2/ IGF-II Protein, Untagged, E.coli-1mg

QP5264-1mg 1mg
EUR 1513.2

Recombinant Human IGF-2/ IGF-II Protein, Untagged, E.coli-10ug

QP5264-10ug 10ug
EUR 163.2

Recombinant Human IGF-2/ IGF-II Protein, Untagged, E.coli-50ug

QP5264-50ug 50ug
EUR 284.4

Recombinant Human IGF-BP1 Protein

PROTP08833-1 25ug
EUR 380.4
Description: IGF-BPs controls the distribution, function and activity of IGFs in various cell tissues and body fluids. Currently there are seven named IGF-BPs that form high affinity complexes with both IGF-I and IGF-II. IGF-BP1 is a 25.4 kDa cysteine-rich secreted protein expressed in liver, deciduas, and kidneys and is the most abundant IGF-BP in amniotic fluid. Levels of IGF-BP1 in serum are lowest after food. IGF-BP1 binds to both IGF-I and IGF-II with equal affinity. Phosphorylated IGF-BP1 hinders IGF actions, where as nonphosphorylated IGF-BP1 is stimulatory. Recombinant human IGF-BP1 is a 25.4 kDa protein consisting of 235 amino acid residues (Isoform A).

Recombinant Human IGF-BP3 Protein

PROTP17936-2 25ug
EUR 380.4
Description: IGF-BP3 is a 30 kDa cysteine-rich secreted protein. It is the major IGF binding protein present in the plasma of human and animals and it is also found in α-granules of platelets. In addition to its ability to modulate the activity of IGF-I and IGF-II, IGF-BP3 exerts inhibitory effects on follicle stimulating hormone (FSH) activity. Decreased plasma levels of IGF-BP3 often results in dwarfism, whereas elevated levels of IGF-BP3 may lead to acromegaly. The expression of IGF-BP3 in fibroblasts is stimulated by mitogenic growth factors such as Bombesin, Vasopressin, PDGF, and EGF. Recombinant human IGF-BP3 is a 28.8 kDa protein consisting of 264 amino acid residues.

Recombinant Human IGF-BP2 Protein

PROTP18065 20ug
EUR 380.4
Description: IGF-BPs controls the distribution, function and activity of IGFs in various cell tissues and body fluids. Currently there are seven named IGF-BPs that form high affinity complexes with both IGF-I and IGF-II. IGF-BP2 is a cysteine-rich secreted protein produced by bone cells, and is most abundant in the brain. IGF-BP2 has been shown to inhibit IGF-II action in human breast and ovarian carcinoma cells. Recombinant human IGF-BP2 is a 31.5 kDa protein consisting of 289 amino acid residues including the IGF-BP domain and thyroglobulin type-I domain.

*Manufactured using (BTI-Tn-5B1-4) cells under license from the Boyce Thompson Institute for Plant Research, Inc.

Recombinant Human IGF-BP6 Protein

PROTP24592-2 20ug
EUR 380.4
Description: IGF-BPs controls the distribution, function and activity of IGFs in various cell tissues and body fluids. IGF-BP6 is produced by bone cells and is the major IGF-BP present in cerebrospinal fluid, and specifically inhibits IGF-II actions. IGF-BP6 has been shown to inhibit IGF-II-dependent cancers such as neuroblastoma, colon cancer and rhabdomyosarcoma. Recombinant human IGF-BP6 has a calculated mass of 22.6 kDa and consists of 213 amino acid residues including the IGF-BP domain and thyroglobulin type-I domain. IGF-BP6 migrates at an apparent molecular weight of approximately 23.0-30.0 kDa by SDS-PAGE analysis under non-reducing conditions.

*Manufactured using (BTI-Tn-5B1-4) cells under license from the Boyce Thompson Institute for Plant Research, Inc.

Recombinant Human IGF-BP5 Protein

PROTP24593-1 25ug
EUR 380.4
Description: IGF-BPs controls the distribution, function and activity of IGFs in various cell tissues and body fluids. Currently there are seven named IGF-BPs that form high affinity complexes with both IGF-I and IGF-II. IGF-BP5 is a 28.6 kDa cysteine-rich secreted protein produced by vascular smooth muscle cells. It is the major IGF-binding protein present in bone tissue and helps potentiate the action of IGF-I on smooth muscle cells, fibroblasts or osteoblasts. Data shows that IGFBP-5 acts as a growth inhibitor and pro-apoptotic agent in breast cancer cells. IGFBP-5 overexpressing mice show an increase in neonatal mortality, reduced female fertility, whole-body growth inhibition and retarded muscle development. Recombinant human IGF-BP5 is a 28.6 kDa protein consisting of 253 amino acid residues.

Recombinant Human IGF-BP7 Protein

PROTQ16270-2 25ug
EUR 380.4
Description: IGF-BPs controls the distribution, function and activity of IGFs in various cell tissues and body fluids. Currently there are seven named IGF-BPs that form high affinity complexes with both IGF-I and IGF-II. IGF-BP7 is expressed in a wide range of normal human tissues and it generally shows reduced expression in cancer cell lines of prostate, breast, colon, and lung origin. It plays a role in skeletal myogenesis by binding to IGF in a manner that inhibits IGF induced differentiation of skeletal myoblasts, without affecting IGF induced proliferation. Additionally, IGF-BP7 suppresses growth and colony formation of prostate and breast cancer cell lines through an IGF independent mechanism, which causes a delay in the G1 phase of the cell cycle, and increased apoptosis. Recombinant human IGF-BP7 is a 26.4 kDa protein consisting of 256 amino acid residues.

Recombinant Human IGF-2/ IGF-II Protein, Untagged, E.coli-100ug

QP5264-100ug 100ug
EUR 435.6

Recombinant Human IGF-2/ IGF-II Protein, Untagged, E.coli-500ug

QP5264-500ug 500ug
EUR 914.4

IGF-1, DES1-3, human

RC216-12B 100ug
EUR 203.56

Zapalenie skórno-mięśniowe z dodatnim przeciwciałem anty-MDA5 z szybko postępującą śródmiąższową chorobą płuc: opis dwóch przypadków

Ar melanomas diferenciāciju saistītais proteīns 5 (MDA5) antivielu pozitīvais dermatomiozīts (DM) parāda unikālas ādas un patoloģiskās iezīmes. Mēs aprakstām divus ar miozītu saistītas ātri progresējošas intersticiālas plaušu slimības (RP-ILD) gadījumus.

Pacientes bija divas sievietes no Keralas, Indijā. Abiem pacientiem bija anti-MDA5 antivielu pozitīvs miozīts. Abiem pacientiem bija RP-ILD bez jebkādām miozīta klīniskām pazīmēm un viņi pakļāvās savai slimībai, neraugoties uz agresīvu ārstēšanu. Anti-MDA5-antivielu pozitīvam DM raksturīga amiopātiska slimība ar strauji progresējošu un letālu ILD.

Przeciwciała przeciwko dekarboksylazie glutaminianowej w surowicy a zaburzenia neurologiczne: kiedy podejrzewać ich związek?

Mērķi: Izpētīt dažādas neiroloģiskas izpausmes ar aizdomām par saistību ar seruma glutamāta dekarboksilāzes antivielām (GAD-Abs), lai labāk raksturotu anti-GAD neiroloģiskos sindromus.

Metodes: Novērošanas retrospektīvais pētījums, kurā tika iekļauti visi pacienti, kuriem La Pazas Universitātes slimnīcas Neiroloģijas nodaļa laika posmā no 2015. līdz 2019. gadam pieprasīja GAD65-Abs titru serumā. GAD-Abs mērīja ar ELISA. Tika pētīti demogrāfiskie dati, neiroloģiskie simptomi, blakusslimības ar cukura diabētu (DM) vai citu autoimūno slimību un GAD-Abs titri. Stingras personas sindroms, ataksija, encefalīts un epilepsija tika uzskatīti par tipiskiem anti-GAD neiroloģiskiem sindromiem un tika salīdzināti ar citām netipiskām izpausmēm.

Rezultāti: Kopumā tika iekļauti 173 pacienti (51,7% vīriešu, vidējais vecums 51,62). Pēdējo 5 gadu laikā pakāpeniski palielinājās seruma GAD-Abs pieprasījumu skaits, īpaši pacientiem ar netipiskām neiroloģiskām izpausmēm. GAD-Abs tika konstatēti 22 pacientu serumā (12,7%); no tiem 15 (68,18%) cieta tipisku anti-GAD sindromu.

DM vai citas orgānspecifiskas autoimūnas slimības klātbūtne paredzēja GAD-AB seropozitivitāti (p <0,001). 6,6% no pieprasītajiem pacientiem ar netipisku sindromu bija GAD-Abs, guess seruma līmenis bija ievērojami zemāks nekā konstatēts pacientiem ar tipisku sindromu (706,67 vs 1430,23 UI / ml; Mann-Whitney U, p = 0,034), un beidzot diagnosticēta cita neiroloģiska slimība.

Secinājums: serumā GAD-Abs reti tika konstatēti pacienti ar klīniskiem fenotipiem, izņemot tos, kas klasiski aprakstīti kā anti-GAD traucējumi, un ar ļoti zemu titru. Tipiskos anti-GAD sindromos ir augsta saslimstība ar DM un citām autoimūnām slimībām, un parasti ir augsts GAD-Abs līmenis serumā.

Podwójne dodatnie wyniki przeciwciał przeciwko β 2 -glikoproteinie I domenie I i przeciw fosfatydyloserynie / protrombinie wzmacniają zarówno zakrzepicę, jak i dodatni wynik przeciwciał anty-ADAMTS

Lai gan ar iegūto trombotisko trombocitopēnisko purpuru (TTP) rodas daži antifosfolipīdu sindromi (APS), saistība starp antifosfolipīdu antivielām (aPL) un anti-ADAMTS13 (anti-a dezintegrīnu un metalloproteāzi ar 1. tipa trombospondīna motīvu, 13. loceklis) paliek nenoteikta.

Mēs pētījām saikni starp augsta riska trombotisko aPL un anti-ADAMTS13 antivielām. Tika iekļauti divi simti trīsdesmit septiņi pacienti ar pozitīvu vilkēdes antikoagulantu un / vai antikardiolipīna antivielu. Tika izmērīti anti-β2GPI (anti-β2-glikoproteīns I), anti-β2GPIdI (anti-β2-glikoproteīna I domēns I), anti-PS / PT (antifosfatidilserīns un protrombīns), ADAMTS13 aktivitāte un anti-ADAMTS13 antiviela.

Divkārša anti-β2GPI un anti-PS / PT pozitivitāte palielināja trombozes risku vairāk nekā trīs reizes un parādīja paaugstinātu anti-ADAMTS13 antivielu pozitivitāti, salīdzinot ar dubultnegatīvo grupu.

Dubultā pozitīvā anti-β2GPIdI un anti-PS / PT parādīja abus efektus vēl vairāk. Lineārajā regresijas analīzē anti-β2GPI un anti-PS / PT dubultā pozitivitāte neatkarīgi ietekmēja antivielu līmeni anti-ADAMTS13 (β = 1,982, P = 0,042).

Mūsu rezultāti atklāja, ka anti-β2GPI vai anti-β2GPIdI un anti-PS / PT dubultā pozitivitāte palielināja ne tikai trombotisko risku, guess arī anti-ADAMTS13 antivielu pozitivitāti, īpaši norādot, ka anti-β2GPIdI parādīja augstāku sinerģisko efektu ar anti-PS / PT.

Mēs iesakām iespējamu anti-ADAMTS13 antivielu saistību ar augstu APS trombotisko risku.

Anti-β2GPI (anti-β2-glikoproteīns I) un anti-PS / PT (anti-fosfatidilserīns un protrombīns) antivielu dubultā pozitivitāte palielināja ne tikai trombotisko risku, guess arī anti-ADAMTS13 (anti-dezintegrīna un metaloproteāzes ar trombospondīna tipa) pozitivitāti 1 motīvs, loceklis 13) antivielas.

Turklāt anti-β2GPIdI (anti-β2-glikoproteīna I domēns I) dubultā pozitivitāte kombinācijā ar anti-PS / PT vēl vairāk paaugstināja gan trombozi, gan anti-ADAMTS13 antivielu pozitivitāti. Tika konstatēts, ka dubultā pozitivitāte β2GPI un anti-PS / PT kā neatkarīgi nozīmīgs faktors anti-ADAMTS13 antivielu līmeņa paaugstināšanai. Mēs iesakām saistību starp anti-ADAMTS13 antivielām un antifosfolipīdu sindroma patofizioloģiju, kas būtu tālāk jāizvērtē.

Add a Comment

Jūsu e-pasta adrese netiks publicēta. Obligātie lauki ir atzīmēti kā *